Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Board Meeting
SMS Pharmaceuticals Ltd scheduled a Board meeting on 1 Aug 2026 to consider and approve unaudited standalone and consolidated financial results for Q1 ended 30 Jun 2026. Trading window closed from 01 Jul to 03 Aug 2026.
Board Meeting
SMS Pharmaceuticals Ltd: Board to meet on 2026-08-01 to consider and approve unaudited standalone & consolidated financial results for quarter ended 30 June 2026; trading window closed 01 Jul–03 Aug 2026.
Regulatory/Compliance Filing
SMS Pharmaceuticals published newspaper ads on 22-Jul-2026 notifying shareholders of transfer of shares to IEPF for unpaid/unclaimed dividend for FY2018-19; claim deadline given as 25-Oct-2026.
Regulatory/Compliance Filing
SMS Pharmaceuticals Ltd published a newspaper notice (22-07-2026) informing shareholders that shares related to unpaid/unclaimed dividend for FY 2018-19 will be transferred to the IEPF if not claimed by Oct 25, 2026.
Regulatory/Compliance Filing
SMS Pharmaceuticals Ltd sent reminder letters on 22-Jul-2026 to shareholders with unclaimed dividends for 7+ years; instructs claims by 25-Oct-2026 or shares will be transferred to the Investor Education and Protection Fund (IEPF).
Regulatory/Compliance Filing
SMS Pharmaceuticals dispatched reminder letters on 22 July 2026 to shareholders with unclaimed dividends for 7+ years; shares will be transferred to IEPF if not claimed by 25 October 2026. Claim instructions via RTA provided.
SMS Pharmaceuticals Ltd (SMSPHARMA) is currently trading at 386.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
SMS Pharmaceuticals Limited manufactures Active Pharma Ingredients (APIs) and intermediates, with multiple FDA-compliant facilities in Hyderabad and Andhra Pradesh. The company is a leader in the production of APIs and leverages its extensive R&D capabilities to maintain its market position. The company reported an 80% year-on-year increase in profit after tax for Q2 FY26, driven by a strategic focus on backward integration and volume growth across key APIs. A major ₹280 crore capital expenditure program is underway, aimed at expanding production capacities and enhancing the company's market footprint by November 2026. SMS Pharmaceuticals maintains a diversified product portfolio across over 55 APIs in 14 therapeutic segments, mitigating market risks and enhancing revenue stability. Strategic partnerships, such as the joint venture with Chemo, have significantly bolstered the company's position in the regulated markets, leading to first-to-market advantage in the anti-diabetic segment.
Over the past 52 weeks, SMS Pharmaceuticals Ltd has traded between a low of ₹208.20 and a high of ₹446.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
SMS Pharmaceuticals Ltd has a market capitalization of approximately 3,566.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
SMS Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.97 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,566.27 Cr, SMS Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
SMS Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of SMS Pharmaceuticals Ltd is 34.97. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
6
Bullish
6
Bearish
21
Neutral
6
Bullish
19
Bearish
19
Neutral
0
Bullish
13
Discovery themes featuring this stock
SMS Pharmaceuticals Limited manufactures Active Pharma Ingredients (APIs) and intermediates, with multiple FDA-compliant facilities in Hyderabad and Andhra Pradesh. The company is a leader in the production of APIs and leverages its extensive R&D capabilities to maintain its market position.
The company reported an 80% year-on-year increase in profit after tax for Q2 FY26, driven by a strategic focus on backward integration and volume growth across key APIs.
A major ₹280 crore capital expenditure program is underway, aimed at expanding production capacities and enhancing the company's market footprint by November 2026.
SMS Pharmaceuticals maintains a diversified product portfolio across over 55 APIs in 14 therapeutic segments, mitigating market risks and enhancing revenue stability.
Strategic partnerships, such as the joint venture with Chemo, have significantly bolstered the company's position in the regulated markets, leading to first-to-market advantage in the anti-diabetic segment.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,566 Cr
High Risk
35.0
36.7
0.9
4.5
446.50
208.20
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1657.35 | 4,067 Cr | 41.60 | 4.97 | 0.00 | 11.39 | 15.94 | 9.99 | ||
360.50 | 3,928 Cr | 84.23 | 13.65 | 0.19 | 16.22 | 14.47 | 9.27 | ||
539.90 | 3,797 Cr | 46.37 | 1.40 | 0.00 | 2.88 | 3.79 | 6.77 | ||
377.85 | 3,793 Cr | 59.10 | 5.70 | 0.03 | 9.66 | 11.45 | 4.78 | ||
405.05 | 3,693 Cr | 18.94 | 2.38 | 0.49 | 12.58 | 11.51 | 6.92 | ||
386.60 | 3,566 Cr | 34.97 | 4.54 | 0.11 | 12.98 | 12.14 | 6.46 | ||
53.88 | 2,947 Cr | 39.55 | 2.36 | 0.37 | 5.96 | 7.58 | 4.94 | ||
| Median: 7 Co. | — | 386.60 | 3,793 Cr | 41.60 | 4.54 | 0.11 | 11.39 | 11.51 | 6.77 |
